Last reviewed · How we verify
RUC-4 Compound
At a glance
| Generic name | RUC-4 Compound |
|---|---|
| Also known as | Placebo |
| Sponsor | CeleCor Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4 (PHASE1)
- A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RUC-4 Compound CI brief — competitive landscape report
- RUC-4 Compound updates RSS · CI watch RSS
- CeleCor Therapeutics portfolio CI